Skip to content

Journal of Psychiatric Research

ISSN 1879-1379, 0022-3956

99 papers in the library · 1,202 citations · publishing 1996-2026

Papers

Sort Most recent Most cited

Sexual minority identifiers and their perception of illicit drug use risks in the US: Results from a National Survey.

Journal of Psychiatric Research July 1, 2024 Yen-Han Lee, Yen-Chang Chang, Mack Shelley et al. 6 citations

This study examined the relationship between sexual identities and perception of risks associated with illicit drug use among a nationally representative sample of US adults. We analyzed data from five waves of the National Survey on Drug Use and Health (NSDUH, 2015-2019), with 205,418 adult participants. Six survey questions assessing participants' perceptions of the risks associated with...

DOI: 10.1016/j.jpsychires.2024.05.010 (opens in new tab) Full text (opens in new tab) Sexual minority Substance abuse prevention Lgbtq+ health disparities Drug risk perception +2

Efficacy of Esketamine among patients with treatment resistant depression in a 'real world' health-care setting in Israel.

Journal of Psychiatric Research June 1, 2024 Lior Dvorak, Esther Bloemhof-Bris, Assaf Shelef et al. 9 citations

One in five people will likely suffer from major depressive disorder (MDD) during their life. Thirty percent of those with MDD will experience Treatment Resistant Depression (TRD), which is characterized by a failure to respond to two adequately administered trials of antidepressants. Esketamine is a rapidly acting intranasal antidepressant. Present-day Esketamine research has limited data in...

Oral prolonged-release ketamine in treatment-resistant depression - A double-blind randomized placebo-controlled multicentre trial of KET01, a novel ketamine formulation - Clinical and safety results.

Journal of Psychiatric Research May 1, 2024 Michael Colla, Benjamin Offenhammer, Hanne Scheerer et al. 23 citations

We investigated the antidepressant effects of a novel oral prolonged-release formulation of racemic ketamine (KET01) in patients suffering from treatment-resistant depression (TRD) as add-on therapy. Patients were randomized to an additional 160 mg/day or 240 mg/day KET01 or placebo for 14 days. The primary endpoint was change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores from...

DOI: 10.1016/j.jpsychires.2024.03.002 (opens in new tab) Full text (opens in new tab) Depression Ketamine therapy Mental health treatment Clinical trials +1

Cortical thickness of the posterior cingulate cortex is associated with the ketamine-induced altered sense of self: An ultra-high field MRI study.

Journal of Psychiatric Research April 1, 2024 Lena Vera Danyeli, Zümrüt Duygu Sen, Lejla Colic et al. 3 citations

Subanesthetic doses of ketamine induce an antidepressant effect within hours in individuals with treatment-resistant depression while it furthermore induces immediate but transient psychotomimetic effects. Among these psychotomimetic effects, an altered sense of self has specifically been associated with the antidepressant response to ketamine as well as psychedelics. However, there is plenty...

Psychological and attentional outcomes following acute mindfulness induction among high anxiety individuals: A systematic review and meta-analysis.

Journal of Psychiatric Research February 1, 2024 Monique Williams, Cynthia Honan, Sarah Skromanis et al. 9 citations

Training outcomes of mindfulness interventions for anxiety have been extensively researched. Less is known about the acute effects of mindfulness induction and associated mechanisms. This systematic review aimed to identify 1) the effect of mindfulness induction on pre-post measures of state anxiety and attention among adults experiencing high levels of anxiety; and 2) the impact of predictors,...

Mindfulness training modifies attentional bias to facial emotion and emotional symptoms.

Journal of Psychiatric Research November 1, 2023 Hui Kou, Wei Luo, Xinnan Liu et al. 11 citations

Mindfulness training has been shown to improve emotional symptoms such as anxiety and depressive symptoms. However, its cognitive-behavioral mechanism is still unclear. The present study aimed to investigate the effect of mindfulness training on attention to emotional faces and its role in the improvement in emotional symptoms. Eighty participants were recruited and randomly divided into a...

Imagery rescripting as a short intervention for symptoms associated with mental images in clinical disorders: A systematic review and meta-analysis.

Journal of Psychiatric Research October 2023 Julia Kroener, Lisa Hack, Benjamin Mayer et al.

There is an unmet need for effective short-term therapeutic techniques to reduce clinical symptoms associated with prospective-, as well as retrospective aversive mental images across mental disorders. We investigated the efficacy of imagery rescripting (IR) as a short-term intervention across clinical disorders, as the literature suggests that this technique could be a promising intervention...

DOI: 10.1016/j.jpsychires.2023.09.010 (opens in new tab) Full text (opens in new tab) Clinical disorders Imagery rescripting Intervention Mental imagery +2

Arketamine for bipolar depression: Open-label, dose-escalation, pilot study.

Journal of Psychiatric Research August 1, 2023 Igor D. Bandeira, Gustavo C. Leal, Fernanda S. Correia-Melo et al.

There are significantly fewer options for the treatment of bipolar depression than major depressive disorder, with an urgent need for alternative therapies. In this pilot study, we treated six subjects with bipolar disorder types I and II (according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria) who had been in a current depressive episode for at...

Effects of low-dose ketamine infusion on vascular endothelial growth factor and matrix metalloproteinase-9 among patients with treatment-resistant depression and suicidal ideation.

Journal of Psychiatric Research July 1, 2023 Mu-Hong Chen, Wei-Chen Lin, Cheng-Ta Li et al. 8 citations

BACKGROUND Evidence indicates that vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) influence the pathophysiology of depression. However, whether low-dose ketamine regulates VEGF and MMP-9 levels and whether changes in VEGF and MMP-9 levels are associated with the antidepressant and antisuicidal effects of ketamine remained unclear. METHODS Forty-eight patients...

Molecular brain differences and cannabis involvement: A systematic review of positron emission tomography studies.

Journal of Psychiatric Research June 2023 Hui Xu, Max M Owens, Troy Farncombe et al.

An increasing number of studies have used positron emission tomography (PET) to investigate molecular neurobiological differences in individuals who use cannabis. This study aimed to systematically review PET imaging research in individuals who use cannabis or have cannabis use disorder (CUD). Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses criteria, a...

DOI: 10.1016/j.jpsychires.2023.03.045 (opens in new tab) Full text (opens in new tab) Cannabis use disorder Dopamine Endocannabinoid system Positron emission tomography

Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder.

Journal of Psychiatric Research May 1, 2023 Franklin R. Schneier, Jamie D. Feusner, Michael G. Wheaton et al. 79 citations

Body dysmorphic disorder (BDD) is an often-severe condition in which individuals are preoccupied by misperceptions of their appearance as defective or ugly. Only serotonin reuptake inhibitors and cognitive-behavioral therapy have been demonstrated efficacious in randomized controlled trials. Psilocybin is a psychedelic drug with growing evidence for safety and efficacy in treatment of...

DOI: 10.1016/j.jpsychires.2023.03.031 (opens in new tab) Full text (opens in new tab) Psilocybin Body dysmorphic disorder Clinical trial Psychedelic treatment +4

Effects of a online brief modified mindfulness-based stress reduction therapy for anxiety among Chinese adults: A randomized clinical trial.

Journal of Psychiatric Research May 2023 Minghuan Wang, Han Zhang, Xiaofan Zhang et al.

The COVID-19 pandemic has exacerbated anxiety and related symptoms among the general population. In order to cope with the mental health burden, we developed an online brief modified mindfulness-based stress reduction (mMBSR) therapy. We performed a parallel-group randomized controlled trial to evaluate the efficacy of the mMBSR for adult anxiety with cognitive-behavioral therapy (CBT) as an...

DOI: 10.1016/j.jpsychires.2023.03.009 (opens in new tab) Full text (opens in new tab) Anxiety disorders Cognitive-behavioral therapy Mental health Randomized clinical trial

Speech graph analysis in obsessive-compulsive disorder: The relevance of dream reports.

Journal of Psychiatric Research March 28, 2023 Matilde Gomes, Maria Picó Pérez, Inês Castro et al.

Obsessive-compulsive disorder (OCD) is a distressing disorder characterized by the presence of intrusive thoughts, images or urges (obsessions) and/or behavioral efforts to reduce the anxiety (compulsions). OCD lifetime prevalence varies between 1% and 3% in the general population and there are no reliable markers that support the diagnosis. In order to fill this gap, Computational Psychiatry...

Cortical inhibition function is associated with baseline suicidal symptoms and post-ketamine suicidal symptom reduction among patients with treatment-resistant depression and strong suicidal ideation.

Journal of Psychiatric Research March 1, 2023 Mu-Hong Chen, T. Su, Li-Fen Chen et al.

BACKGROUND Whether cortical excitation and inhibition functions differ between patients with treatment-resistant depression (TRD) and strong suicidal ideation (SI) and healthy subjects and whether 0.5 mg/kg ketamine infusion can modulate cortical excitation and inhibition functions among patients with TRD-SI remain unclear. METHODS A total of 29 patients with TRD-SI and 35 age- and sex-matched...

Multiplicity in the experience of voice-hearing: A phenomenological inquiry.

Journal of Psychiatric Research December 1, 2022 Chris R Brewin, Kirsty Phillips, John Morton et al. 2 citations

Although it is recognized that voice-hearers often report a large number and variety of voices there have been few investigations of this multiplicity. Understanding the phenomenology of voice-hearing can provide a firm foundation for theorizing about its causes. In this international online survey of voice-hearers, details were elicited of the content of up to five utterances associated with...

The neuroscience of spirituality, religion, and mental health: A systematic review and synthesis.

Journal of Psychiatric Research December 1, 2022 David H Rosmarin, Caroline C Kaufman, Stephanie Friree Ford et al.

Prior research highlights the importance of spirituality/religion (S/R) as it relates to several aspects of mental health and clinical interventions. This research has been expanded to include the concurrent examination of neurobiological correlates of S/R to elucidate potential biological mechanisms. However, the majority of neurobiological research on S/R has neglected mental health, and the...

Chronic cannabis use affects cerebellum dependent visuomotor adaptation.

Journal of Psychiatric Research October 6, 2022 C. Blithikioti, L. Miquel, B. Paniello et al.

BACKGROUND Cannabis is one of the most commonly used substances in the world. However, its effects on human cognition are not yet fully understood. Although the cerebellum has the highest density of cannabinoid receptor type 1 (CB1R) in the human brain, literature on how cannabis use affects cerebellar-dependent learning is sparse. This study examined the effect of chronic cannabis use on...

Surface-based brain morphometry in schizophrenia vs. cannabis-induced psychosis: A controlled comparison.

Journal of Psychiatric Research September 1, 2022 Abhishek Ghosh, Simranjit Kaur, Raghav Shah et al.

BACKGROUND & AIM We examined group differences in cortical thickness and surface-parameters among age and handedness--matched persons with cannabis-induced psychosis (CIP), schizophrenia with heavy cannabis use (SZC), and healthy controls (HC). METHODS We recruited 31 men with SZC, 28 with CIP, and 30 with HC. We used the Psychiatric Research Interview for Substance and Mental Disorders to...

Default mode network alterations underlie auditory verbal hallucinations in schizophrenia.

Journal of Psychiatric Research August 1, 2022 Marco Marino, C. Spironelli, Dante Mantini et al.

Although alterations of the default mode network (DMN) in schizophrenia (SZ) have been largely investigated, less research has been carried out on DMN alterations in different sub-phenotypes of this disorder. The aim of this pilot study was to compare DMN features among SZ patients with and without auditory verbal hallucinations (AVH). Three groups of 17 participants each were considered:...

Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis.

Journal of Psychiatric Research May 1, 2022 Yazen Alnefeesi, David C J Chen-Li, Ella Krane et al. 177 citations

Ketamine is a promising therapeutic option in treatment-resistant depression (TRD). The acute efficacy of ketamine in TRD has been demonstrated in replicated randomised-controlled trials (RCTs), but the generalizability of RCT data to real-world practice is limited. To this end, we conducted a systematic review (Search date: 25/12/2021; 1482 records identified) and meta-analysis of studies...

The abuse liability of ketamine: A scoping review of preclinical and clinical studies.

Journal of Psychiatric Research May 1, 2022 Tuyen T. Le, Isabel Pazos Cordero, Muhammad Youshay Jawad et al. 82 citations

While ketamine has been used clinically over the past decades, it has only been recently shown to be a promising therapy for treatment-resistant depression (TRD). However, ketamine and related dissociative agents may also be misused recreationally, creating significant concerns for abuse liability when prescribed for depression. Although the abuse potential of ketamine is widely recognized,...

MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD.

Journal of Psychiatric Research May 1, 2022 Timothy D Brewerton, Julie B. Wang, Adele Lafrance et al. 81 citations

Eating disorders (EDs) and posttraumatic stress disorder (PTSD) are highly comorbid, yet there are no proven integrative treatment modalities for ED-PTSD. In clinical trials, MDMA-assisted therapy (MDMA-AT) has shown marked success in the treatment of PTSD and may be promising for ED-PTSD. Ninety individuals with severe PTSD received treatment in a double-blind, placebo-controlled pivotal trial...

Timing of Cannabis Exposure Relative to Prodrome and Psychosis Onset in a Community-Based First Episode Psychosis Sample

Journal of Psychiatric Research 2022 E. Kline, M. Ferrara, Fang-Yong Li et al.

Cannabis has been implicated as both a potential cause and adverse prognostic factor in psychotic disorders. Investigating the contributory role of cannabis toward the overall burden of psychotic illnesses may represent an important step toward psychosis prevention and treatment. The current study samples consecutive admissions (N = 246) to two community based first-episode psychosis services...

Putting mindfulness-based cognitive therapy to the test in routine clinical practice: A transdiagnostic panacea or a disorder specific intervention?

Journal of Psychiatric Research October 2021 Dirk E. M. Geurts, N Marlou Haegens, Marleen H.C.T. van Beek et al.

Over the past two decades there has been a growing number of randomized clinical trials supporting the efficacy of mindfulness-based cognitive therapy (MBCT) in the treatment of several psychiatric disorders. Since evidence for its effectiveness in routine clinical practice is lagging behind, we aimed to examine adherence, outcome and predictors of MBCT in a well-characterized, heterogeneous...

The resilient phenotype elicited by ketamine against inflammatory stressors-induced depressive-like behavior is associated with NLRP3-driven signaling pathway.

Journal of Psychiatric Research September 30, 2021 A. Camargo, A. P. Dalmagro, Ingrid A V Wolin et al.

Ketamine has emerged as a prophylactic agent against depressive-like behavior induced by stress. However, the possible pro-resilience effects of ketamine against inflammatory stressors-induced depressive-like behavior and the signaling pathways associated with this response remain to be determined. Therefore, this study investigated the ability of prophylactic ketamine administration to produce...